Hadassah University Hospita Ein Kerem

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Multiple myeloma3 trials
• Acute myeloid leukaemia2 trials
• Atrial fibrillation1 trial
• Childhood cancers1 trial
• Chronic lymphocytic leukaemia1 trial
• Chronic myeloid leukaemia1 trial
• Colorectal cancer1 trial
• Coronary artery disease1 trial
• Hodgkin lymphoma1 trial
• Myelodysplastic syndromes1 trial
• Myeloproliferative neoplasms1 trial
• Prostate cancer1 trial

Phase

• Phase 36 trials
• Phase 13 trials
• Phase 1/21 trial

Status

• Active, not recruiting4 trials
• Recruiting4 trials
• Completed1 trial
• Enrolling by invitation1 trial

Lead sponsor

• Janssen Research & Development, LLC10 trials

Running trials

• Recruiting

  A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  NCT06852222· Phase 3· Janssen Research & Development, LLC· Source

• Enrolling by invitation

  A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

  NCT06788509· Phase 1· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

  NCT06662786· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT06425991· Phase 1· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

  NCT06150157· Phase 1· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

  NCT04923893· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

  NCT04811560· Phase 1/2· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma

  NCT04181827· Phase 3· Janssen Research & Development, LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute myeloid leukaemia2 recruiting
• Childhood cancers1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Colorectal cancer1 recruiting
• Hodgkin lymphoma1 recruiting
• Myelodysplastic syndromes1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source